Nazli Dizman, MD, Yale University School of Medicine, New Haven, CT, discusses unmet needs regarding immunotherapy (IO) for renal cell carcinoma, including the need for biomarkers to accurately identify patients who will benefit from IO and strategies to optimize IO benefit, including changing the timings of administration of immunotherapy. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
